Abstract
Glatiramer acetate (GA) is one of the most widely used disease-modifying drugs for the treatment of relapsingremitting multiple sclerosis; is assumed to have inductor effects on neurotrophic factor expression. One of these neurotrophic factor systems is the brain-derived neurotrophic factor (BDNF)/receptor tyrosine kinase B (TrkB) pathway. Peripheral blood is thought to contain soluble BDNF, and some blood cells express TrkB. We attempted to determine whether GA treatment leads to changes in plasma BDNF levels and TrkB activation. Such a phenomenon are relapsingremitting multiple sclerosis patients is significantly reduced; GA treatment is not influencing peripheral BDNF levels, after one year of sustained therapy, not from the point of view of total free BDNF nor the phosphorylated TrkB.
Keywords: Brain-derived neurotrophic factor, glatiramer acetate, multiple sclerosis, receptor tyrosine kinase B.
CNS & Neurological Disorders - Drug Targets
Title:Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing- Remitting Multiple Sclerosis
Volume: 13 Issue: 4
Author(s): Vitalie Vacaras, Zsigmond Z. Major, Dafin F. Muresanu, Tibor L. Krausz, Ioan Marginean and Dana A. Buzoianu
Affiliation:
Keywords: Brain-derived neurotrophic factor, glatiramer acetate, multiple sclerosis, receptor tyrosine kinase B.
Abstract: Glatiramer acetate (GA) is one of the most widely used disease-modifying drugs for the treatment of relapsingremitting multiple sclerosis; is assumed to have inductor effects on neurotrophic factor expression. One of these neurotrophic factor systems is the brain-derived neurotrophic factor (BDNF)/receptor tyrosine kinase B (TrkB) pathway. Peripheral blood is thought to contain soluble BDNF, and some blood cells express TrkB. We attempted to determine whether GA treatment leads to changes in plasma BDNF levels and TrkB activation. Such a phenomenon are relapsingremitting multiple sclerosis patients is significantly reduced; GA treatment is not influencing peripheral BDNF levels, after one year of sustained therapy, not from the point of view of total free BDNF nor the phosphorylated TrkB.
Export Options
About this article
Cite this article as:
Vacaras Vitalie, Major Z. Zsigmond, Muresanu F. Dafin, Krausz L. Tibor, Marginean Ioan and Buzoianu A. Dana, Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing- Remitting Multiple Sclerosis, CNS & Neurological Disorders - Drug Targets 2014; 13 (4) . https://dx.doi.org/10.2174/1871527313666140618110049
DOI https://dx.doi.org/10.2174/1871527313666140618110049 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Other Future Targeting Therapy Beyond TNF-α Inhibitor in Patients with Spondyloarthropathy
Current Rheumatology Reviews Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets In vitro And In vivo Immunomodulating Properties of Mesenchymal Stem Cells
Recent Patents on Inflammation & Allergy Drug Discovery A Case Presentation of Atypical X-linked Adrenoleukodystrophy: Initial Experience with ASL Technique
Current Medical Imaging Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models
Inflammation & Allergy - Drug Targets (Discontinued) Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Vitamin D and Cystic Fibrosis Lung Disease
Mini-Reviews in Medicinal Chemistry Glutamate Receptors in Microglia
CNS & Neurological Disorders - Drug Targets